[{"search_type":"general-inventory-search","vehicle_array":[{"trim":"High Altitude","make":"Jeep","cat":"hybrid_suv","year":"2024","customer_id":"5358035","certified ...

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...

The Fathom Blue example you see here is one of those pickups. Moreover, it's one of those even rarer examples that still pack a numbers-matching drivetrain. The result of an extensive nut-and-bolt ...

Shares of PHAT opened at $4.40 on Monday. Phathom Pharmaceuticals has a twelve month low of $4.35 and a twelve month high of $19.71. The company has a market capitalization of $300.86 million, a P ...

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) has been given an average rating of “Buy” by the six analysts that are presently covering the stock, Marketbeat.com reports.

Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $19 from $27 and keeps a Buy rating on the shares. The firm notes Phathom’s Q4 ...

Phathom Pharmaceuticals Inc (NASDAQ:PHAT) secured FDA approval for non-erosive GERD, enhancing their product portfolio. The company reported strong commercial coverage, with over 120 million lives ...

Goldman Sachs lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $12 from $18 and keeps a Neutral rating on the shares after its FY24 results. The company’s product revenue ...

Revenue: US$55.3m (up by US$54.6m from FY 2023). Net loss: US$334.3m (loss widened by 66% from FY 2023). US$5.29 loss per share (further deteriorated from US$3.93 loss in FY 2023). Revenue ...

Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call. At this time, all participants are in a listen-only mode. After the presentation ...